Prospective study of thromboembolism risk assessment tool in patients with advanced lung cancer:Validation study of Rising-VTE/CS-Lung008

Prospective study of thromboembolism risk assessment tool in patients with advanced lung cancer:Validation study of Rising-VTE/CS-Lung008 - Rising Score Validation Study

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000053138

Enrollment

300

Registered

2023-12-18

Start date

2024-01-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-small cell lung cancer, small cell lung cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Pathologically diagonosed non-small cell or small cell lung cancer ECOG PS 0-3 Age over 20 years old Small cell lung cancer for which radical surgery, radiation therapy, or chemoradiotherapy is not possible (LD or ED) Non-small cell lung cancer for which radical surgery, radiation therapy, or chemoradiotherapy is not possible (regardless of stage) Reccurence of operation or concurrent chemoradiotherapy Best supportive care patient 6 months or longer expected survival Written informed consent

Exclusion criteria

Exclusion criteria: none

Design outcomes

Primary

Measure	Time frame
Rising score calculated using the incidence of new venous thoromboembolism in 2 years	—

Secondary

Measure	Time frame
Over all survival	—

Countries

Japan

Contacts

Public ContactHirotoki Tsuda

Shimane University Faculty of Medicine Department of Internal Medicine Division of Medical Oncology & Respiratory Medicine

t.hirotoki@med.shimane-u.ac.jp0853-20-2580

Outcome results